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Objectives. This study evaluated cardiac beta-adrenoceptor 
responsiveness in the elderly. 
Background. The hypothesis of reduced cardiac beta-adrenoceptor 
responsiveness in the elderly is based on a smaller increase in heart 
rate after administration of isoproterenol, a nonselective betas- and 
beta2-adrenoceptor agonist. By means of dobutamine-stress- 
eehocardiography we were able to retest the hypothesis more 
accurately because dobutamine is a relatively selective beta~- 
adrenoceptor agonist with weak beta 2- and alpha-adrenoceptor 
stimulant activity that prevents baroreflex-mediated changes in 
heart rate. 
Methods. After administration of stepwise incremental infu- 
sions of dobutamine, we measured heart rate and blood pressure 
responses in 360 patients who had no beta-adrenergic blocking 
agent therapy and no side effects during the stress test. For each 
patient we calculated the dose of dobutamine required to increase 
heart rate by 50% of the maximal heart rate during the highest 
dose of dobutamine. 
Results. No relation was found between age and sensitivity to 
dobutamine (n = 293). Power analysis revealed that this negative 
finding was not the result of inadequate sample size. In contrast 
to the prevailing hypothesis, an increased heart rate response to 
dobutamine was found even in a subgroup of "healthy" elderly 
subjects (i.e., those without concomitant disease or acute myocar- 
dial ischemia, n = 67) that was not related to changes in blood 
pressure during stress. However, in subjects with acute ischemia 
(n = 109), smokers (n = 151) or patients with a history of a 
previous myocardial infarction (n = 148), dobutamine sensitivity 
was reduced in the elderly despite a diminished change in systolic 
blood pressure with advanced age during dobutamine infusion. 
This phenomenon could be explained by a decrease in efferent 
cardiac baroreflex sensitivity, as has been observed during acute 
myocardial ischemia. There were no age-related differences in 
plasma concentrations of dobutamine. 
Conclusions. No evidence for reduced beta-adrenoceptor re- 
sponsiveness to dobutamine was found in "healthy" elderly sub- 
jects. 
(J Am CoU Cardiol 1995;25:995-9) 
Adrenergic responsiveness in humans changes with aging (1,2). 
Changes in responses to neurotransmitters may have impor- 
tant clinical consequences for drug therapy in elderly subjects. 
The beta-adrenoceptor hasbeen the subject of extensive phar- 
macologic and physiologic studies (3-6). Beta-adrenoceptor acti- 
vation induces a positive inotropic and chronotropic effect on 
the heart, and betaz-adrenoceptor stimulation induces vascular 
relaxation. The beta-l-adrenoceptor is thought o become less 
sensitive with aging. Evidence for this hypothesis circumstan- 
tial: Basal concentrations of norepinephrine are increased in 
the elderly, and beta-adrenoceptor densities and affinities are 
unchanged (2); yet, the chronotropic response to bolus infu- 
sions of isoproterenol (a betas- and beta2-adrenoceptor stim- 
ulant) in older animals and senescent humans is decreased 
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(4,7,8). In the elderly, the reduced effect of isoproterenol n 
heart rate may be caused by an attenuated direct chronotropic 
response mediated by beta l- and betaz-adrenoceptors  a 
reduced activation of the baroreflex in response to beta 2- 
adrenoceptor-mediated vasodilation i duced by isoproterenol. 
In previous animal studies (7,8), chiefly in the rat, baroreflexes 
were intact, and isoproterenol was given as a bolus injection. In 
pithed rats, where the baroreflex response was eliminated, no 
difference was found in the chronotropic effect of isoprotere- 
nol in young and elderly rats (5). 
The present study evaluates the chronotropic responsive- 
ness to incremental stepwise infusions of dobutamine, a rela- 
tively selective betal-adrenoceptor agonist with weak alpha- 
and beta2-adrenoceptor stimulant activity in relatively low 
dosages (9), which, in contrast to isoproterenol, does not evoke 
the baroreflex-induced changes in heart rate induced by vaso- 
dilation (10). Our analysis is based partly on a previously 
published study of dobutamine stress echocardiography (11). 
Data for subjects with hypertension, diabetes mellitus, previ- 
ous myocardial infarction, angina pectoris, echocardiographic 
evidence of myocardial ischemia during dobutamine infusion 
and a history of smoking were analyzed separately. 
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Methods  
Patient characteristics. Four hundred fifty-one patients 
underwent dobutamine stress echocardiography during the 
period 1992 to 1994. Patients taking a beta-adrenergic blocking 
agent and those who experienced side effects during dobut- 
amine infusion, necessitating interruption of the test, were 
excluded from this study, leaving a total of 360 patients for 
analysis (243 men, 117 women; mean age 61 years, range 22 to 
90). One hundred twelve patients (31%) were >70 years old; 
148 (41%) had a previous myocardial infarction; 104 (28%) 
had angina pectoris; 39 (11%) had diabetes mellitus (with drug 
therapy); and 123 (34%) had hypertension, defined as sus- 
tained elevated iastolic blood pressure ->90 mm Hg with or 
without drug treatment. Indications for examination were 
evaluation of chest pain (n = 123 [34%]) and preoperative 
cardiac risk stratification (n = 237 [66%]) (11). Dobutamine 
plasma concentrations were measured uring the test in 34 
patients (mean age 62 years, range 40 to 77). 
Dobutamine stress test, The dobutamine stress protocol 
was approved by the hospital ethics committee. After giving 
informed consent, the patients underwent a two-dimensional 
echocardiographic examination at rest. Dobutamine was ad- 
ministered intravenously with an infusion pump, starting at 
10/xg/kg body weight per rain for 3 rain, followed by stepwise 
increments of 10/xg/kg per rain every 3 rain to a maximum of 
40/xg/kg per rain. The dobutamine infusion was stopped if the 
target heart rate (85% of a theoretic maximal heart rate was 
achieved: for men, (220 - age) x 85%; for women, (200 - 
age) × 85% (12). Blood pressure and heart rate were mea- 
sured at rest and at every infusion step with an automatic 
device (Accutorr A1, Datascope Corp.). A 12-lead electrocar- 
diogram (ECG) was recorded at rest and at the end of every 
dose step. The two-dimensional echocardiogram was moni- 
tored continuously and recorded on videotape during the last 
minute of every dose step. Criteria for interruption of the test 
were horizontal or downsloping ST segment depression 
>2 mm at 80 ms after the J point; ST segment elevation; 
severe, continuous chest pain; reduction in systolic blood 
pressure >40 mm Hg from baseline or a systolic blood 
pressure <100 mm Hg; significant cardiac arrhythmias; or any 
side effect regarded as caused by dobutamine. Off-line assess- 
ment of echocardiographic images was performed by two 
investigators (D.P., P.M.F.) Reduced wall thickening and new 
wall motion abnormalities are the hallmarks of ischemia (13). 
A new wall motion abnormality was defined as an increase in 
score between rest and stress. 
Dobutamine measurement in plasma. Blood samples were 
taken at the end of every dose step. Dobutamine was measured 
in plasma as described by Alberts et al. (14). In brief, after a 
liquid/liquid extraction and derivatization with the fluorogenic 
agent 1,2-diphenylethylenediamine, dobutamine was measured 
by fluorometric detection after separation by high performance 
liquid chromatography. 
Statistical analysis. The effect of dobutamine on blood 
pressure was assessed by the paired t test. By linear regression 
analysis the equations of the heart rate-log dose-response 
curves were calculated for each individual patient. The sensi- 
tivity for dobutamine was calculated as EDso-HR, which is the 
dose required to increase heart rate by 50% of the maximum at 
the highest dose of dobutamine. "Healthy" patients were 
defined as those without he presence of any of the clinical 
variables (angina, previous infarction, hypertension, diabetes 
and smoking) and acute myocardial ischemia. Dobutamine 
sensitivity, systolic and diastolic blood pressure change in 
relation to clinical variables and acute myocardial ischemia 
(echocardiographically detected ischemia, ECG changes or 
angina during dobutamine infusion) were compared between 
various groups and between healthy subjects by multivariate 
linear regression analysis, including an interaction term. A two- 
tailed p value <0.05 was required for significance. A power 
analysis was performed to determine the possibility of a beta- 
error. All data are expressed as mean value _+ SD. 
Resu l ts  
Heart rate increased from 72 _+ 8 to 132 + 14 beats/min 
(p = 0.0001, n = 360). Systolic blood pressure increased uring 
dobutamine infusion from 144 _+ 24 to 150 _+ 28 mm Hg (p = 
0.001). Diastolic blood pressure decreased from 82 _+ 12 to 
76 _+ 18 mm Hg at the maximal dose of dobutamine (p = 0.01). 
Ages for all subjects as well as for various subgroups by 
clinical variable are presented in Table 1. Between-group 
comparisons did not reveal statistically significant differences 
in age, except for subjects with a history of angina pectoris (p = 
0.02). 
Between-group comparisons of EDso-HR for all subjects as 
well as for various subgroups did not reveal statistically signif- 
icant differences in dobutamine s nsitivity (Table 1). 
No relationship was found between age and sensitivity to 
dobutamine (n = 293). In this group, a slope (EDs0-HR vs. 
age) of less than -0.07 would have been detected with a power 
of 80%. Subsequently within-group analyses of the relation 
between age and EDs0-HR were performed. In four groups a 
relation was found between age and EDso-HR (p < 0.05): 
"healthy" subjects, in whom an increased sensitivity was noted 
with advancing age (p = 0.03); and subjects with a previous 
myocardial infarction (p = 0.01), those with acute myocardial 
ischemia (p = 0.03) and those who smoked (p = 0.03), in 
whom a decreased sensitivity was noted with advancing age. 
This higher sensitivity ofthe "healthy" elderly to dobutamine 
was not related to the reduced increase in systolic pressure dur- 
ing dobutamine infusion (EDso-HR vs. systolic blood pressure 
change [ram Hg], p = 0.12) (Table 1). Diastolic blood pressure 
remained unchanged in healthy elderly subjects and in different 
subgroups. 
In all subjects, except for those classified as "healthy" or 
diabetic, a positive correlation was present between systolic 
blood pressure increment and EDs0-HR, which may be ex- 
plained by an inhibition of dobutamine-induced tachycardia by
a baroreflex-mediated increase in vagal activity to the heart, 
which inhibits the chronotropic response to dobutamine. 
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Table 1. Influence of Age on Heart Rate and Blood Pressure Response to Infusion of Dobutamine and Relation of Dobutamine-Induced 
Heart Rate Response Versus Systolic Blood Pressure Change 
EDso-HR Change in SBP Change in EDso-HR 
Versus Age Versus Age Versus SBP 
EDso-HR 
No. of Age (yr) p (~tg/kg per p p p p p p p 
Pts (mean -+ SD) Value* rain) Value* Slope Value? Value,,--' Slope Value? Values Slope Value? Values 
All patients 293 61.8 -+ 1.4 0.06§ 20.9 0.16§ +0.05 0.06§ 0.007 -0.42 0.002 0.14§ +0.05 0.003 0.90§ 
Diabetes 39 62.1 _+ 4.1 0.22§ 20.5 0.15§ +0.10 0.15§ 0.02 +0.13 0.82§ 0.04 +[I.04 0.32§ 0.90§ 
Hypertension 123 62.l _+ 1.9 0.08§ 21.(/ 0.22§ 0.03 (I.50§ 0.06§ -0.23 0.34§ 0.06§ +0.08 0.005 0.70§ 
Smoking 151 61.4 _+ 2.0 0.06§ 21.0 0.25§ +0.08 ([.(13 0.003 0.40 0.005 0.15§ +0.06 0.003 0.90§ 
History of AP 104 59.4 + 2.2 0.02 21.1 0.2§ 0.07 0.21§ 0.08§ -0.68 0.00l 0.90§ +0.06 0.04 0.90§ 
History of MI 148 61.2 _+ 1.8 0.06§ 20.8 0.1§ +0.11 0.01 0.003 -0.40 0.002 0.15§ +0.07 0.004 0.80§ 
Acute ischemia 109 6(I.2 + 2.1 0.06§ 21.6 0.62§ +0.11 0.03 0.003 0.52 0.004 0.40§ +0.05 0.01 1.0§ 
"Healthy" 67 65.0 + 2.9 21.9 -0.14 0.03 (I.69 0.002 +0.05 0.12§ 
*Unpaired t test of subgroups versus "healthy" patients, tStepwise logistic regression analysis on slopes of linear regression analysis within one subgroup. -Stepwise 
logistic regression analysis on slopes of linear regression analysis between subgroups of patients and "healthy" patients. §Not significant. Acute ischemia = presence 
of new wall motion abnormalities or electrocardiographic changes or angina pectoris (AP) during stress; DBP (SBP) - diastolic (systolic) blood pressure change 
(ram Hg) during dobutamine infusion; EDs,-HR dobutamine dose required to achieve 50% of maximal heart rate; "Healthy" - absence of smoking, hypertension, 
diabetes mellitus, previous myocardial infarction (MI) and ischemia during stress. 
In subjects who smoked or who had a previous myocardial 
infarction, a decreased sensitivity to dobutamine was found in 
the elderly despite a diminished increase in systolic blood 
pressure change during dobutamine infusion. In subjects with 
a history of angina no relation was present between age and 
dobutamine sensitivity despite a decrease in systolic blood 
pressure change. In subjects with acute myocardial ischemia, a
reduced sensitivity in the elderly was present despite an 
unchanged systolic blood pressure (a comparison between 
healthy subjects and those with acute ischemia is presented in 
Fig. 1). All four subgroups (history of infarction or angina, 
smoking or acute ischemia) showed evidence of a reduced 
dobutamine sensitivity in elderly patients. 
In senescent subjects with diabetes or hypertension, no 
relation between age and sensitivity to dobutamine or systolic 
blood pressure change was found. The relation of age and 
EDso-HR in "all" patients, acute ischemia, smoking, diabetes 
and a previous myocardial infarction was significantly different 
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Figure 1. Changes in heart rate 
(left) and systolic blood pressure 
(right) during dobutamine infusion 
in "healthy" patients with no diabe- 
tes, hypertension, smoking, previous 
myocardial infarction or echocardio- 
graphic evidence of myocardial isch- o 
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Table 2. Increase inPlasma Concentrations f Dobutamine During 
Different Test Stages in Patients -<60 and >60 Years Old 
Dobutamine Plasma Concentration ( g/ml) 
Dobutamine Infusion Age -<60 yr Age >60 yr p 
(/zg/kg per min) (n = 20) (n = 14) Value 
0 0 0 NS 
10 32 _+ 17 26 _+ 9 NS 
20 220 + 55 220 _+ 43 NS 
30 552 _+ 62 542 _+ 59 NS 
40 917 z 118 910 + 90 NS 
Data presented are mean value _+ SD. 
from those of healthy subjects (Table 1). They all showed a 
reduced obutamine s nsitivity compared with that in healthy 
subjects, which could only be explained on the basis of systolic 
blood pressure changes during the test in subjects with diabe- 
tes, whereas the relation of EDso-HR and systolic blood 
pressure change was not different. Analyses of the sensitivity to 
dobutamine in absolute terms (beats/min) rather than relative 
changes (ED5o-HR) yielded similar results. 
During dobutamine infusion there was a large variation in 
plasma dobutamine concentration between i dividual subjects. 
When subjects >60 and <60 years old were compared, there 
was no significant interpatient difference in the increase of 
dobutamine plasma concentrations during the stress test be- 
tween these two groups (Table 2). 
Discuss ion  
The effects of aging on beta-adrenoceptor-mediated re- 
sponses have been studied mainly by observing the chrono- 
tropic effects of bolus injections of isoproterenol in rats (7,8). 
The finding of reduced cardiac hronotropic responsiveness to 
beta-adrenoceptor stimulation by isoproterenol has been con- 
firmed in humans, where elderly subjects were screened for the 
absence of coronary artery disease by history and physical 
examination only (3,4). A decreased heart rate response to 
isoproterenol in the elderly can be caused by a reduced irect 
beta 1- or beta2-adrenoceptor-mediated chronotropic response 
or a reduced baroreflex sensitivity to beta2-adrenoceptor- 
mediated vasodilation occurring during isoproterenol infusion. 
A study by Docherty et al. (5) in pithed rats, where the 
baroreflex interference was abolished, showed no difference of 
isoproterenol-induced tachycardia in young and old rats. 
In contrast to isoproterenol, dobutamine has little effect on 
blood pressure because of its weak stimulation of alphas- and 
beta2-adrenoreceptors in peripheral blood vessels in the low 
dose range. Indeed, in our study diastolic blood pressure did 
not increase but in fact decreased significantly, but only by an 
average of 6 mm Hg. The cardiac hronotropic effect of dobut- 
amine is mainly due to betal-adrenoceptor stimulation (9). 
Beta-adrenoceptor and aging. The present study shows no 
evidence of reduced beta-adrenoceptor sensitivity to dobut- 
amine in senescent subjects. In subgroups of "healthy" elderly 
subjects (i.e., those without diabetes, hypertension, smoking 
and angina and with normal echocardiographic findings at rest 
with no evidence of ischemia during dobutamine stress), an 
increased sensitivity for dobutamine-induced tachycardia was 
found. In these healthy subjects this response could not be 
explained by a reduced increase in systolic pressure in the 
elderly because there was no correlation between blood pres- 
sure changes and dobutamine s nsitivity. Compared with pre- 
vious findings, the present results might be explained by the 
absence of silent coronary artery disease in otherwise appeal- 
ingly healthy elderly subjects because dobutamine stress echo- 
cardiography testing is a highly sensitive method for detecting 
silent myocardial ischemia (13). 
Effect of acute myocardial ischemia. In the present study 
we found a decreased sensitivity to dobutamine in elderly 
subjects with acute myocardial ischemia during stress. Hage- 
man et al. (15) recently described an attenuated baroreflex 
sensitivity and reduced efferent cardiac sympathetic activity 
during experimental cute myocardial ischemia in a canine 
model. Such a phenomenon could have contributed to the 
apparent reduced sensitivity to dobutamine in our subjects 
with acute myocardial ischemia induced by dobutamine. In
subjects with diabetes or hypertension, o relation between age 
and sensitivity to dobutamine orbetween heart rate and blood 
pressure changes and dobutamine sensitivity was found. In 
patients with diabetes this may be explained by autonomic 
neuropathy (16). In subjects with long-standing hypertension, 
reduced baroreflex sensitivity might contribute to this phenom- 
enon. 
In senescent subjects with a previous myocardial infarction, 
angina and smoking a reduced or unchanged heart rate 
response to dobutamine was observed espite a diminished 
increase in systolic blood pressure during the test in the 
elderly, indicating that there was indeed a reduced sensitivity 
in the elderly subjects in the four subgroups. The mechanism of
this finding in the absence of acute ischemia during the 
dobutamine stress echocardiography test remains obscure. 
Pharmaeokinetie data. Pharmacokinetic data on dobut- 
amine in humans are scant. The pharmacokinetic model of 
dobutamine is that of a first-order derivate, indicated by the 
linear plasma correlation between infusion rate and concen- 
tration (17,18). These previous studies investigated obut- 
amine infusions between 2.5 and 10/zg/kg per rain, in contrast 
to the present study in which the maximal dose was 40 ~g/kg 
per min. However, pharmacokinetic changes in dobutamine in 
the elderly, as a possible explanation for our findings, are in 
our view unlikely because in a study of 34 subjects we found 
no-age related differences in plasma dobutamine concentra- 
tions during infusions. 
Conclusions. Sensitivity for dobutamine-induced tachycar- 
dia is not reduced in the elderly unless there is evidence of 
ischemic heart disease. Moreover, an increased sensitivity was 
found even in "healthy" elderly subjects. 
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